Literature DB >> 2940336

Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington's disease compared to schizophrenics and controls.

J J Mann, R D Kaplan, E D Bird.   

Abstract

Activity (Vmax) of monoamine oxidase (MAO) B in necropsy samples from the head of the caudate nucleus was 260% higher in patients dying with Huntington's disease (HD) than in controls (P less than 0.05). No differences in MAO A enzyme kinetics were found. MAO B, but not MAO A, was increased (26%) in the frontal cortex from patients dying with HD compared to control subjects. MAO A and B kinetics in caudate nucleus and frontal cortex from a group of schizophrenics did not differ from controls. Postmortem delay, the effect of neuroleptics, or nonspecific degeneration artifacts did not explain these findings. It is suggested that the increase in MAO B activity in the caudate nucleus may reflect neurochemical changes that are responsible for the choreiform movements of Huntington's disease. Lower cortical MAO B activity in the schizophrenic group may reflect the effects of neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940336     DOI: 10.1007/bf01249088

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  18 in total

1.  GABA content and glutamic acid decarboxylase activity in brain of Huntington's chorea patients and control subjects.

Authors:  N Urquhart; T L Perry; S Hansen; J Kennedy
Journal:  J Neurochem       Date:  1975-05       Impact factor: 5.372

2.  Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea.

Authors:  P L McGeer; E G McGeer
Journal:  J Neurochem       Date:  1976-01       Impact factor: 5.372

3.  Various enzymes involved with putative neurotransmitters. Regional distribution in the brain of deceased mentally normal, chronic schizophrenics or organic brain syndrome patients.

Authors:  E F Domino; R R Krause; J Bowers
Journal:  Arch Gen Psychiatry       Date:  1973-08

4.  Multiple forms of brain monoamine oxidase in schizophrenic and normal individuals.

Authors:  M A Schwartz; R J Wyatt; H Y Yang; N H Neff
Journal:  Arch Gen Psychiatry       Date:  1974-10

5.  Ageing, monoamines, and monoamine-oxidase levels.

Authors:  D S Robinson; A Nies; J N Davis; W E Bunney; J M Davis; R W Colburn; H R Bourne; D M Shaw; A J Coppen
Journal:  Lancet       Date:  1972-02-05       Impact factor: 79.321

6.  Central cholinergic-anticholinergic antagonism in Huntington's chorea.

Authors:  H L Klawans; R Rubovits
Journal:  Neurology       Date:  1972-02       Impact factor: 9.910

7.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

8.  Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia.

Authors:  E D Bird; L L Iversen
Journal:  Brain       Date:  1974-09       Impact factor: 13.501

9.  Platelet monoamine oxidase activity in Huntington's chorea.

Authors:  J Mann; E Chiu
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-09       Impact factor: 10.154

10.  Monoamine oxidase-A and -B activities in the brain stem of schizophrenics and non-schizophrenic psychotics.

Authors:  C J Fowler; A Carlsson; B Winblad
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

View more
  9 in total

1.  Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography.

Authors:  S M Aquilonius; S S Jossan; J G Ekblom; H Askmark; P G Gillberg
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Imaging of neuroinflammation.

Authors:  Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12       Impact factor: 9.236

Review 3.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

4.  Effect of neurocatin on the activity of monoamine oxidase B in rat brain synaptosomes.

Authors:  S Murphy; A Pastuszko
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

5.  The Neuroprotective Effect of Antidepressant Drug via Inhibition of TIEG2-MAO B Mediated Cell Death.

Authors:  Deyin Lu; Chandra Johnson; Shakevia Johnson; Shawna Tazik; Xiao-Ming Ou
Journal:  Drug Discov Ther       Date:  2008-10

6.  Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis.

Authors:  Shawna Tazik; Shakevia Johnson; Deyin Lu; Chandra Johnson; Moussa B H Youdim; Craig A Stockmeier; Xiao-Ming Ou
Journal:  Neurotox Res       Date:  2009-02-28       Impact factor: 3.911

7.  Kinetic modeling of the monoamine oxidase B radioligand [¹¹C]SL25.1188 in human brain with high-resolution positron emission tomography.

Authors:  Pablo M Rusjan; Alan A Wilson; Laura Miler; Ian Fan; Romina Mizrahi; Sylvain Houle; Neil Vasdev; Jeffrey H Meyer
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

Review 8.  Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases.

Authors:  P Dostert; M Strolin Benedetti; G Dordain
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

9.  Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease.

Authors:  Jolene Ooi; Michael R Hayden; Mahmoud A Pouladi
Journal:  Mol Neurobiol       Date:  2014-11-15       Impact factor: 5.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.